<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220614055172N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-03</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Ondansetron and Ginger on Nausea/ Vomiting, Shivering and Headache in Cesarean Section Patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparative Study of the Effect of Ondansetron and Ginger on Nausea/ Vomiting, Shivering and Headache after Spinal Anesthesia during and after Cesarean Section</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-08-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64269</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: In the random block sampling method, different modes of three groups are written on six cards and each in an envelope is placed in the package. These envelopes are placed in a box, and the researcher does not know which research units will be placed in before selecting the card. Before exposure to the research units, the midwife picking up one of the envelopes from the box without awareness of the study and groups determines which group that will be included in the study, respectively, Blinding description: In this study, participants and clinical caregivers and data analyzer will be informed of the generality and method of implementation of the study, but will not be aware of the groups and the type of intervention received That is, the participant, clinical caregiver and data analyzer will be unaware of where each participant is and what intervention has received.</study_design>
      <phase>3</phase>
      <hc_freetext>Cesarean section.</hc_freetext>
      <i_freetext>Intervention 1: First Intervention group: This group is the ginger group, which will first be prepared as Zintoma oral capsules (250 mg) produced by Gol Daroo Pharmaceutical Company. Then, 1000 mg ginger capsule will be prepared in the pharmacology laboratory of Hamadan University of Medical Sciences under the supervision of a pharmacist. After coordination with the anesthesia team and the gynecological surgery team, the patient will be given a ginger capsule (1000 mg) with 30 ml of water one hour before receiving spinal anesthesia. Intervention 2: Second Intervention group: This group is ondansetron group, which will first be prepared as ondansetron tablets (16 mg) produced by Exir Pharmaceutical Company. After coordination with the anesthesia team and the gynecological surgery team, the patient will be given an ondansetron capsule (16 mg) with 30 ml of water one hour before receiving spinal anesthesia. Intervention 3: Control group: Placebo capsule (containing rice flour) will be prepared in the pharmacology laboratory of Hamadan University of Medical Sciences under the supervision of a pharmacist. After coordination with the anesthesia team and gynecological surgery team, a placebo capsule (containing rice flour) with 30 ml of water one hour before The patient will be given spinal anesthesia.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All personal data is shared after unidentified individuals. Includes demographic data and data on the severity of Nausea/Vomiting, Shivering, and Headache.

When:
The data is shared three months after the publication of the results.

To whom:
All researchers can apply for the data.

Conditions:
The data is provided provided that they first have a clear purpose for using the data. Secondly, wherever this data is to be used, the primary data source should be mentioned.

Where to obtain:
Can use the the following e-mail address to receive the data.
Behzadiman@yahoo.com

How to obtain:
After sending the request to the e-mail address, the data will be sent as soon as possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sahar Alizade</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>In front of Mardom's Park, Shahid Fahmideh Street, Pazhouhesh Square,</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517838736</zip>
        <telephone>+98 81 3131 0000</telephone>
        <email>arielalizade@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Imani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>In front of Mardom's Park, Shahid Fahmideh Street, Pazhouhesh Square,</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517838736</zip>
        <telephone>+98 81 3131 0000</telephone>
        <email>Behzadiman@yahoo.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age range of 20 to 40 years
Physical status 1 or 2 in terms of ASA criteria
Complete gestational age and singleton
Cesarean candidate under spinal anesthesia</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Unwilling to participate in the study
History of mental disorders
Body mass index greater than 35
Meniere's disease
Digestive Disease
Frequent Dora holes and failed spinal anesthesia
Allergy to Ondansetron or Ginger</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z38.01</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Single liveborn infant, delivered by cesarean</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First Intervention group: This group is the ginger group, which will first be prepared as Zintoma oral capsules (250 mg) produced by Gol Daroo Pharmaceutical Company. Then, 1000 mg ginger capsule will be prepared in the pharmacology laboratory of Hamadan University of Medical Sciences under the supervision of a pharmacist. After coordination with the anesthesia team and the gynecological surgery team, the patient will be given a ginger capsule (1000 mg) with 30 ml of water one hour before receiving spinal anesthesia.</i_keyword>
      <i_keyword>Second Intervention group: This group is ondansetron group, which will first be prepared as ondansetron tablets (16 mg) produced by Exir Pharmaceutical Company. After coordination with the anesthesia team and the gynecological surgery team, the patient will be given an ondansetron capsule (16 mg) with 30 ml of water one hour before receiving spinal anesthesia.</i_keyword>
      <i_keyword>Control group: Placebo capsule (containing rice flour) will be prepared in the pharmacology laboratory of Hamadan University of Medical Sciences under the supervision of a pharmacist. After coordination with the anesthesia team and gynecological surgery team, a placebo capsule (containing rice flour) with 30 ml of water one hour before The patient will be given spinal anesthesia.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nausea based on visual analog scale score. Timepoint: During cesarean section (20 minutes after the start of surgery), when leaving the recovery (30 minutes after surgery is completed), 1, 2 and 4 hours after the surgery is completed. Method of measurement: Visual analog scale.</prim_outcome>
      <prim_outcome>Vomiting based on the vomiting frequency checklist. Timepoint: During cesarean section (20 minutes after the start of surgery), when leaving the recovery (30 minutes after surgery is completed), 1, 2 and 4 hours after the surgery is completed. Method of measurement: Vomiting frequency checklist.</prim_outcome>
      <prim_outcome>Shivering based on the standard shivering scale score. Timepoint: During cesarean section (20 minutes after the start of surgery), when leaving the recovery (30 minutes after surgery is completed), 1, 2 and 4 hours after the surgery is completed. Method of measurement: Standard Shivering scale based on Crossley and Mahajan criteria.</prim_outcome>
      <prim_outcome>Headache based on visual analog scale score. Timepoint: During cesarean section (20 minutes after the start of surgery), when leaving the recovery (30 minutes after surgery is completed), 1, 2 and 4 hours after the surgery is completed. Method of measurement: Visual analog scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-25</approval_date>
        <contact_name>Ethics committee of Hamadan University of Medical Sciences</contact_name>
        <contact_address>In front of Mardom's Park, Shahid Fahmideh Street, Pazhouhesh Square Hamadan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
